SYNGENE Stock Overview
A contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Syngene International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹786.80 |
| 52 Week High | ₹860.25 |
| 52 Week Low | ₹607.65 |
| Beta | 0.57 |
| 11 Month Change | 12.06% |
| 3 Month Change | 12.63% |
| 1 Year Change | -2.51% |
| 33 Year Change | 25.75% |
| 5 Year Change | 163.19% |
| Change since IPO | 406.71% |
Recent News & Updates
Recent updates
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Jul 16
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Mar 28Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?
Feb 14Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)
Jan 19Is Syngene International (NSE:SYNGENE) A Risky Investment?
Nov 19Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?
Nov 01Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly
Aug 07These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Apr 28Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching
Apr 06Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Jan 04Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet
Dec 08Is Syngene International (NSE:SYNGENE) Using Too Much Debt?
Aug 28Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate
Aug 10These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well
May 10Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?
Feb 02Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Nov 26Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly
Sep 21Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock
Aug 06Shareholder Returns
| SYNGENE | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 2.6% | 0.9% | -1.0% |
| 1Y | -2.5% | 16.2% | 43.6% |
Return vs Industry: SYNGENE underperformed the Indian Life Sciences industry which returned 17.9% over the past year.
Return vs Market: SYNGENE underperformed the Indian Market which returned 43.2% over the past year.
Price Volatility
| SYNGENE volatility | |
|---|---|
| SYNGENE Average Weekly Movement | 2.7% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SYNGENE has not had significant price volatility in the past 3 months.
Volatility Over Time: SYNGENE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 6,510 | Jonathan Hunt | www.syngeneintl.com |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services.
Syngene International Limited Fundamentals Summary
| SYNGENE fundamental statistics | |
|---|---|
| Market cap | ₹299.25b |
| Earnings (TTM) | ₹4.92b |
| Revenue (TTM) | ₹34.70b |
64.1x
P/E Ratio9.1x
P/S RatioIs SYNGENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNGENE income statement (TTM) | |
|---|---|
| Revenue | ₹34.70b |
| Cost of Revenue | ₹11.49b |
| Gross Profit | ₹23.21b |
| Other Expenses | ₹18.29b |
| Earnings | ₹4.92b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.27 |
| Gross Margin | 66.88% |
| Net Profit Margin | 14.19% |
| Debt/Equity Ratio | 13.0% |
How did SYNGENE perform over the long term?
See historical performance and comparison